Influence of time to first therapy (TTFT) variable on survival outcomes of neoadjuvant chemotherapy versus upfront surgery approach in resectable pancreatic ductal adenocarcinoma

被引：0
|
作者：
Sousa, Aryanna
Pena, Paola
Kwon, Steve
机构：
[1] Roger Williams Canc Outcomes Res & Equ RWCORE Ctr, Providence, RI USA
[2] Roger Williams Med Ctr, Providence, RI USA
[3] Rush Univ Med Ctr, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Kelley, Jesse K.
    Kolbeinsson, Hordur
    Chandana, Sreenivasa
    Eastburg, Benjamin
    Frisch, Austin
    Parker, Jessica
    Wright, G. Paul
    Assifi, M. Mura
    Chung, Mathew
    AMERICAN SURGEON, 2024, 90 (11) : 2762 - 2768
  • [32] A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study'
    Chen, Yuan
    Wang, Chengcheng
    Zhao, Yupei
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (10) : 3209 - 3210
  • [33] Outcomes of Margin Status on Survival in Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Therapy
    Swami, Ashish
    Varshney, Vaibhav Kumar
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2021, 232 (06) : 1022 - 1023
  • [34] ASO Visual Abstract: Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery
    Kitano, Yuki
    Inoue, Yosuke
    Takeda, Tsuyoshi
    Oba, Atsushi
    Ono, Yoshihiro
    Sato, Takafumi
    Ito, Hiromichi
    Ozaka, Masato
    Sasaki, Takashi
    Sasahira, Naoki
    Baba, Hideo
    Takahashi, Yu
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (8) : 5103 - 5104
  • [35] ASO Visual Abstract: Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery
    Yuki Kitano
    Yosuke Inoue
    Tsuyoshi Takeda
    Atsushi Oba
    Yoshihiro Ono
    Takafumi Sato
    Hiromichi Ito
    Masato Ozaka
    Takashi Sasaki
    Naoki Sasahira
    Hideo Baba
    Yu Takahashi
    Annals of Surgical Oncology, 2023, 30 : 5103 - 5104
  • [36] Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma
    Lee, Yoo Na
    Sung, Min Kyu
    Hwang, Dae Wook
    Park, Yejong
    Kwak, Bong Jun
    Lee, Woohyung
    Song, Ki Byung
    Lee, Jae Hoon
    Yoo, Changhoon
    Kim, Kyu-Pyo
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    Kim, Song Cheol
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1240 - 1251
  • [37] Long-term survival of patients receiving multimodality neoadjuvant therapy for resectable or borderline resectable pancreatic ductal adenocarcinoma
    McCormick, Kinsey
    Whiting, Samuel H.
    Gyurkey, Grace
    Koh, Wui-Jin
    Sinanan, Mika
    Coveler, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [38] Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: a systematic review and meta-analysis
    Lee, Yoon Suk
    Lee, Jong-Chan
    Yang, Se Yeol
    Kim, Jaihwan
    Hwang, Jin-Hyeok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 196 - 196
  • [39] Neoadjuvant Therapy Versus Upfront Surgery for Pancreatic Adenocarcinoma: A Propensity Score Matched Analysis of Short-term Outcomes
    Kasumova, G. G.
    De Geus, S. W. L.
    Tabatabaie, O.
    Fadayomi, A. B.
    Ng, S.
    Tseng, J. F.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S125 - S125
  • [40] Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes
    Jung, Ji Hye
    Yoon, So Kyung
    Yoon, So Jeong
    Shin, Sang Hyun
    Han, In Woong
    Heo, Jin Seok
    ANTICANCER RESEARCH, 2021, 41 (11) : 5703 - 5712
12345